What is ENDOCELLUTIONS?
EndoCellutions, Inc. operates at the intersection of biotechnology and clinical efficiency, specializing in advanced point-of-care systems for the preparation of bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP). The company's proprietary technology is engineered to deliver high yields of concentrated viable cells, ensuring consistent separation and intuitive processing for medical practitioners. By focusing on compatibility with standard centrifuges, EndoCellutions provides a distinct competitive advantage, allowing healthcare providers to integrate regenerative therapies seamlessly into existing clinical workflows. Their commitment to precision and ease of use positions them as a critical enabler in the rapidly evolving field of orthobiologics and regenerative medicine.
How much funding has ENDOCELLUTIONS raised?
ENDOCELLUTIONS has raised a total of $41K across 1 funding round:
Debt
$41K
Debt (2021): $41K with participation from PPP
Key Investors in ENDOCELLUTIONS
PPP
Public-Private Partnership
What's next for ENDOCELLUTIONS?
With the recent infusion of capital, EndoCellutions is poised to accelerate its commercial expansion and deepen its penetration into the global regenerative therapy market. The strategic focus will likely shift toward enhancing manufacturing capabilities and expanding the distribution network for its BMAC and PRP processing systems. As the demand for minimally invasive, point-of-care regenerative solutions continues to rise, the company is strategically aligned to capitalize on these industry tailwinds. Future milestones will likely involve further clinical validation of their processing technology and the potential development of next-generation systems that further optimize cell recovery rates, ensuring the company remains at the forefront of medical innovation.
See full ENDOCELLUTIONS company page
